Silo Pharma, Inc. SILO
At closeNov 6, 2026, 7:59 PM EST
After hours · Nov 6, 7:59 PM ET
- YTD
- -73.92%
- 1 year
- -82.00%
- Market cap
- 2.93M
- Revenue (ttm)
- 72.10K
- EPS (ttm)
- -4.26
- Shares out
- 4.48M
- Forward P/E
- -1.26
- YTD return
- -73.92%
- 1-year return
- -82.00%
- Volume
- 35.12K
- Avg volume
- 94.86K
- Open
- 1.26
- Previous close
- 1.29
- Day's range
- 1.25 – 1.37
- 52-week range
- 1.13 – 9.99
- Beta
- 1.36
5D +0.05 (+3.91%)
Key statistics
- Enterprise value
- -2.68M
- PEG ratio
- 0.00
- Price / sales
- 54.94
- Price / book
- 0.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -2.09M
- Total cash
- 7.61M
- Total debt
- 0
- Return on equity
- -48.34%
- Short % of float
- 2.37%
- 50-day average
- 1.04
- 200-day average
- 1.43
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.22 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.31 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.28 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 28, 2023 | Laidlaw & Co. | init | — | Buy |
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- silopharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on SILO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RYWECK DANIEL E. | Chief Financial Officer | Purchase | May 25, 2023 | 5,000 |
| WEISBLUM ERIC | Chief Executive Officer | Purchase | Dec 12, 2024 | 187,932 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.23% | 227,006 | 200.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.03% | 30,761 | 27.17K | Sep 29, 2024 |
| Virtu Financial LLC | 0.03% | 25,615 | 22.63K | Sep 29, 2024 |
| Vanguard Group Inc | 0.02% | 16,334 | 14.43K | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.01% | 6,000 | 5.30K | Sep 29, 2024 |
| State Street Corporation | 0.01% | 12,500 | 11.04K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.02% | 16,334 | 14.43K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.02% | 24,480 | 21.63K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 7,120 | 6.29K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 3,896 | 3.44K | Oct 30, 2024 |